Holen Sie sich die Stockscreener-App
8.31
4.01%
0.32
Schlusskurs vom Vortag:
$7.99
Offen:
$8.25
24-Stunden-Volumen:
8.19M
Relative Volume:
4.30
Marktkapitalisierung:
$608.88M
Einnahmen:
$31,000
Nettoeinkommen (Verlust:
$-54.42M
KGV:
-8.4987
EPS:
-0.9778
Netto-Cashflow:
$-48.99M
1W Leistung:
+1.84%
1M Leistung:
+5.19%
6M Leistung:
+50.00%
1J Leistung:
+68.90%
1-Tages-Spanne:
$7.93
$8.59
1-Wochen-Bereich:
$7.93
$8.92
52-Wochen-Spanne:
$4.35
$9.5699
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
8.31 | 608.88M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics Inc (CADL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Candel Therapeutics Inc (CADL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Candel Therapeutics Inc (CADL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Candel Therapeutics enters new employment agreement with CFO Charles Schoch - Investing.com Nigeria
Candel Therapeutics Inc (CADL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Candel Therapeutics Inc (CADL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Candel Therapeutics Inc (CADL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Candel Therapeutics Inc (CADL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Candel Therapeutics Inc (CADL) Institutional Confidence - TradingKey
Candel Therapeutics enters new employment agreement with CFO Charles Schoch By Investing.com - Investing.com South Africa
Candel Therapeutics (NASDAQ: CADL) sets new pay and severance package for CFO - Stock Titan
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com
Candel Therapeutics Inc (CADL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
When Will Candel Therapeutics, Inc. (NASDAQ:CADL) Breakeven? - 富途牛牛
Candel Therapeutics eyes year-end BLA after strong prostate cancer data - MSN
trust me - Moomoo
Avoiding Lag: Real-Time Signals in (CADL) Movement - Stock Traders Daily
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish - TradingView
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Candel Therapeutics, Inc. posts new long term trial results for aglatimagene besadenovec - Traders Union
Candel Therapeutics stock falls despite phase 3 trial publication - Investing.com
CADL Achieves Significant Milestone in Prostate Cancer Treatment - GuruFocus
Candel publishes phase 3 prostate cancer trial results - Investing.com UK
Candel Therapeutics stock falls despite phase 3 trial publication By Investing.com - Investing.com South Africa
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - The Manila Times
Candel publishes phase 3 prostate cancer trial results By Investing.com - Investing.com Australia
Candel Therapeutics Announces Publication in The Lancet - GlobeNewswire
Bank of America Securities Remains a Hold on Candel Therapeutics (CADL) - The Globe and Mail
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New hires at Candel Therapeutics get 63,000 stock options - Stock Titan
BofA Securities Maintains Candel Therapeutics(CADL.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Discipline and Rules-Based Execution in CADL Response - Stock Traders Daily
Candel Therapeutics reported better-than-feared Q1 loss – but all eyes turn to this pivotal event tomorrow - MSN
Candel Therapeutics (CADL) Edges Higher, Holds Above Key Support LevelHigh Dividend Factor - thelegaladvocate.com
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - simplywall.st
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade - MSN
Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data - TradingView
Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs - Traders Union
Behavioral Patterns of CADL and Institutional Flows - Stock Traders Daily
Candel Therapeutics reports positive phase 3 prostate cancer trial data - MSN
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):